Drug Trial Radar · NCT04210115
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
703
Actual
Start
Feb 28, 2020
Primary completion
Jan 21, 2026
Study completion Jun 26, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in: * participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10 * participants whose tumors express PD-L1 CPS ≥1 * all participants The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to: * EFS in participants whose tumors express PD-L1 CPS ≥10 * EFS in participants whose tumors express PD-L1 CPS ≥1 * EFS in all participants * OS in participants whose tumors express PD-L1 CPS ≥10 * OS in participants whose tumors express PD-L1 CPS ≥1 * OS in all participants
Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Gastroesophageal Junction Carcinoma (GEJC)
- Esophageal Adenocarcinoma (EAC)
Interventions
pembrolizumabBiological
IV infusion
placeboDrug
IV infusion
cisplatinDrug
IV infusion
5-FUDrug
IV infusion
radiotherapyRadiation
external radiation
leucovorinDrug
IV infusion
levoleucovorinDrug
IV infusion
oxaliplatinDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS)Time frame: Up to ~60 months
- Overall Survival (OS)Time frame: Up to ~72 months
Locations
170 sites in 27 countries. Site status is shown where the registry gives one.
MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691)
Long Beach, California
Columbus Regional Research Institute ( Site 0047)
Columbus, Georgia
University of Kansas Cancer Center ( Site 0023)
Westwood, Kansas
Cancer Center of Kansas ( Site 0058)
Wichita, Kansas
University Medical Center ( Site 0035)
New Orleans, Louisiana
Greater Baltimore Medical Center ( Site 0031)
Baltimore, Maryland
Dana Farber Cancer Center ( Site 0034)
Boston, Massachusetts
Henry Ford Hospital ( Site 0685)
Detroit, Michigan
University of Missouri ( Site 0688)
Columbia, Missouri
Renown Regional Medical Center ( Site 0706)
Reno, Nevada
Rutgers Cancer Institute of New Jersey ( Site 0695)
New Brunswick, New Jersey
Weill Cornell Medical College ( Site 0053)
New York, New York
Stephenson Cancer Center ( Site 0044)
Oklahoma City, Oklahoma
Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060)
Portland, Oregon
Allegheny Health Network ( Site 0042)
Pittsburgh, Pennsylvania
Thompson Cancer Survival Center ( Site 0696)
Knoxville, Tennessee
Utah Cancer Specialists ( Site 0697)
Salt Lake City, Utah
Cancer Care Northwest - Spokane Valley ( Site 0036)
Spokane Valley, Washington
University of Wisconsin Hospital and Clinics ( Site 0033)
Madison, Wisconsin
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066)
Buenos Aires, Argentina
CEMIC ( Site 0064)
Buenos Aires, Argentina
Instituto Medico Alexander Fleming ( Site 0063)
Buenos Aires, Buenos Aires F.D., Argentina
Fundacion Favaloro ( Site 0061)
Ciudad de Buenos Aires, Buenos Aires F.D., Argentina
UCL Saint Luc ( Site 0162)
Brussels, Bruxelles-Capitale, Region de, Belgium
UZ Gent ( Site 0163)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 0161)
Leuven, Vlaams-Brabant, Belgium
AZ Delta ( Site 0165)
Roeselare, West-Vlaanderen, Belgium
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081)
São Paulo, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088)
Ijuí, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao ( Site 0087)
Porto Alegre, Rio Grande do Sul, Brazil
Clinica de Oncologia Reichow ( Site 0085)
Blumenau, Santa Catarina, Brazil
Cross Cancer Institute ( Site 0010)
Edmonton, Alberta, Canada
CancerCare Manitoba ( Site 0002)
Winnipeg, Manitoba, Canada
The Ottawa Hospital - Cancer Care ( Site 0008)
Ottawa, Ontario, Canada
Sunnybrook Research Institute ( Site 0012)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0011)
Toronto, Ontario, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005)
Montreal, Quebec, Canada
Centro Investigación del Cáncer James Lind ( Site 0106)
Temuco, Araucania, Chile
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103)
Temuco, Araucania, Chile
Hospital Regional de Concepcion ( Site 0105)
Concepción, Biobio, Chile
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.